Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
09016-cover-AstraZenecacxd.jpg

April 16, 2012 Cover

Volume 90, Issue 16

Companies make headway in understanding epigenetic targets and designing drugs to modulate them

Cover image:

Credit:

Full Article
Volume 90 | Issue 16

All Issues

Business

Controlling The Code

Companies make headway in understanding epigenetic targets and designing drugs to modulate them

  • Drug Candidates Debut

    ACS Meeting News: Perennial session serves up potential drugs for hepatitis, migraine, cancer, and type 2 diabetes

  • Methane: A New ‘Fracking’ Fiasco

    The flood of natural gas production is hoped to slow climate change, but it might just make it worse

  • Revisiting 2007 and 2009 Disclosures

    Medicinal chemists debut five drug candidates and describe their discovery.

ADVERTISEMENT
image name
Pharmaceuticals

GSK2636771 - GlaxoSmithKline

Medicinal chemists debut five drug candidates and describe their discovery.

ADVERTISEMENT
ADVERTISEMENT